The global lung cancer screening software market size is projected to reach USD 45.0 million by 2030, growing at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2030, according to a new report published by Grand View Research, Inc. This steady market growth is primarily attributed to the increasing global incidence of lung cancer as well as the expanding implementation of lung cancer screening programs across various regions. For instance, based on Globocan estimates, approximately 160,068 new cases of lung cancer were reported in the South East Asian region in 2018, underlining the urgent need for improved early detection and screening infrastructure.

A wide array of clinical trials, research studies, and pilot demonstration projects are currently underway around the globe to assess and validate the efficacy of lung cancer screening programs. A notable example is the 2017 launch of a screening pilot trial by Cancer Care Ontario, aimed at individuals classified as high-risk. The supportive role of government initiatives promoting the structured implementation of screening programs, along with increased public awareness regarding early detection of lung cancer, are additional drivers expected to propel the market forward during the forecast period.

In the United States, lung cancer screening programs have been widely embraced, particularly among hospitals and radiological centers, owing to a well-established healthcare infrastructure and proactive screening guidelines. However, in many other parts of the world, especially Latin America and the Middle East, market growth is constrained by several challenges. These include the limited availability of healthcare resources, inadequate funding mechanisms, low levels of public and clinical awareness, and a shortage of skilled healthcare professionals trained in lung cancer screening technologies.

Curious about the Lung Cancer Screening Software Market? Download your FREE sample copy now and get a sneak peek into the latest insights and trends. 

Lung Cancer Screening Software Market Report Highlights

• In 2023, North America accounted for the largest share of global revenue, primarily due to the presence of numerous lung cancer screening initiatives and a favorable reimbursement environment supporting the adoption of such software solutions in the region.

• The Asia Pacific region is projected to exhibit the fastest growth rate throughout the forecast period. This growth is largely attributed to the rising incidence of lung cancer and a notable increase in the number of regional trials and research studies focused on screening and early detection of the disease.

Lung Cancer Screening Software Market Segmentation

Grand View Research has segmented the global lung cancer screening software market based on region:

Lung Cancer Screening Software Regional Outlook (Revenue, USD Thousand, 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o Germany

o UK

o Spain

o France

o Italy

o Russia 

• Asia Pacific

o China

o Japan

o Australia

• Latin America

o Brazil

• Middle East and Africa (MEA)

o South Africa

List Of Key Players Lung Cancer Screening Software Market

• Nuance Communications, Inc.

• Eon

• Koninklijke Philips N.V.

• Siemens Healthineers AG

• Voxel Cloud

• MRS

• PENRAD

• MagView

• FUJIFILM Holdings Corporation

• Medtronic

Order a free sample PDF of the Lung Cancer Screening Software Market Intelligence Study, published by Grand View Research.